TABLE 4.
Association analysis of SNPs with 75% responder status
| SNP |
Patients achieving MMD ≥ 75%, n (%) |
Patients not achieving MMD ≥ 75%, n (%) |
Crude OR (95% CI) | p value | Adjusted OR a (95% CI) | p value |
|---|---|---|---|---|---|---|
| CALCRL rs696574 | ||||||
| CC | 18 (60.0) | 60 (75.0) | 1.60 (0.76–3.34) | 0.21 | 1.50 (0.65–3.47) | 0.34 |
| TC | 11 (36.7) | 17 (21.3) | ||||
| TT | 1 (3.3) | 3 (3.8) | ||||
| CALCRL rs6710852 | ||||||
| TT | 19 (63.3) | 67 (83.8) | 2.13 (0.91–4.95) | 0.08 | 2.36 (0.91–6.10) | 0.08 |
| TG | 11 (36.7) | 11 (13.8) | ||||
| GG | 0 (0) | 2 (2.5) | ||||
| CALCRL rs3213738 | ||||||
| TT | 20 (66.7) | 69 (86.3) | 2.15 (0.90–5.14) | 0.08 | 2.47 (0.92–6.60) | 0.07 |
| TC | 10 (33.3) | 9 (11.3) | ||||
| CC | 0 (0) | 2 (2.5) | ||||
| RAMP1 rs302680 | ||||||
| AA | 21 (70.0) | 62 (77.5) | 1.37 (0.62–3.04) | 0.44 | 1.32 (0.55–3.18) | 0.54 |
| GA | 8 (26.7) | 16 (20.0) | ||||
| GG | 1 (3.3) | 2 (2.5) | ||||
| RAMP1 rs13386048 | ||||||
| GG | 14 (46.7) | 31 (38.8) | 0.90 (0.49–1.65) | 0.74 | 0.89 (0.45–1.78) | 0.74 |
| GA | 11 (36.7) | 38 (47.5) | ||||
| AA | 5 (16.7) | 11 (13.8) | ||||
| RAMP1 rs12995100 | ||||||
| TT | 5 (16.7) | 18 (22.5) | 0.90 (0.47–1.72) | 0.74 | 0.73 (0.35–1.55) | 0.42 |
| TC | 21 (70.0) | 43 (53.8) | ||||
| CC | 4 (13.3) | 19 (23.8) | ||||
| RAMP1 rs12465864 | ||||||
| AA | 21 (70.0) | 51 (63.8) | 0.97 (0.44–2.13) | 0.94 | 0.89 (0.37–2.17) | 0.80 |
| AG | 7 (23.3) | 28 (35.0) | ||||
| GG | 2 (6.7) | 1 (1.3) | ||||
| RAMP1 rs7590387 | ||||||
| CC | 13 (43.3) | 22 (27.5) | 0.53 (0.29–0.99) | 0.048 | 0.55 (0.28–1.10) | 0.09 |
| GC | 14 (46.7) | 38 (47.5) | ||||
| GG | 3 (10.0) | 20 (25.0) | ||||
| RAMP1 rs75822777 | ||||||
| GG | 11 (36.7) | 42 (52.5) | 1.66 (0.87–3.14) | 0.12 | 1.76 (0.85–3.65) | 0.13 |
| GA | 15 (50.0) | 32 (40.0) | ||||
| AA | 4 (13.3) | 6 (7.5) | ||||
| RAMP1 rs302676 | ||||||
| TT | 22 (73.3) | 45 (56.3) | 0.56 (0.24–1.32) | 0.19 | 0.66 (0.26–1.67) | 0.38 |
| TC | 7 (23.3) | 34 (42.5) | ||||
| CC | 1 (3.3) | 1 (1.3) | ||||
| RAMP1 rs11673847 | ||||||
| GG | 19 (63.3) | 54 (67.5) | 1.01 (0.46–2.22) | 0.97 | 1.12 (0.47–2.69) | 0.80 |
| GA | 11 (36.7) | 23 (28.8) | ||||
| AA | 0 (0) | 3 (3.8) | ||||
| RAMP1 rs6431564 | ||||||
| AA | 6 (20.0) | 21 (26.3) | 0.91 (0.48–1.76) | 0.79 | 0.87 (0.41–1.85) | 0.72 |
| AG | 21 (70.0) | 43 (53.8) | ||||
| GG | 3 (10.0) | 16 (20.0) | ||||
| RAMP1 rs4663269 | ||||||
| TT | 6 (20.0) | 19 (23.8) | 1.17 (0.60–2.25) | 0.65 | 0.82 (0.39–1.74) | 0.61 |
| TC | 18 (60.0) | 47 (58.8) | ||||
| CC | 6 (20.0) | 14 (17.5) | ||||
| RAMP1 rs7603344 | ||||||
| AA | 14 (46.7) | 41 (51.3) | 1.35 (0.67–2.70) | 0.40 | 1.69 (0.76–3.72) | 0.20 |
| AG | 13 (43.3) | 36 (45.0) | ||||
| GG | 3 (10.0) | 3 (3.8) | ||||
| RAMP1 rs7578855 | ||||||
| TT | 10 (33.3) | 34 (42.5) | 1.01 (0.56–1.82) | 0.98 | 1.01 (0.52–1.96) | 0.99 |
| CT | 17 (56.7) | 31 (38.8) | ||||
| CC | 3 (10.0) | 15 (18.8) | ||||
Abbreviations: CI, confidence interval; MMD, monthly migraine days; OR, odds ratio; SNP, single nucleotide polymorphism.
a
Logistic regression analysis adjusted by age at migraine onset, number of failed preventive medications, and Migraine Disability Assessment score before erenumab start. Association of SNPs was assessed under the additive genetic model.